Harrow Health(US:HROW)2025-05-08 21:40Financial Performance and Projections - 2025 revenue is expected to be more than $280 million[7] - Adjusted EBITDA for 2024 was $40327 thousand[10] - Consolidated revenues for 2024 were $199614 thousand[10] - ImprimisRx generated $83499 thousand in revenues in 2024[26] Product Launches and Performance - VEVYE Access for All launched in mid-March 2025, leading to a fourfold increase in weekly new prescriptions and prescribers in the first seven weeks[8] - IHEEZO customer unit demand in Q1 2025 reached 38940[14] - VEVYE quarterly prescriptions in Q1 2025 were 72017[17] Strategic Investments and Developments - Harrow holds a 46% ownership in Melt Pharmaceuticals[8] - Melt Pharmaceuticals' MELT-300 showed positive Phase 3 efficacy results, with potential FDA approval and launch in Q1 2027[8] - TRIESENCE has pass-through status granted by CMS effective April 1, 2025[23]